New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the thera...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/7/3887 |
| _version_ | 1797438963763380224 |
|---|---|
| author | Fabio Andreozzi Fulvio Massaro Sebastian Wittnebel Chloé Spilleboudt Philippe Lewalle Adriano Salaroli |
| author_facet | Fabio Andreozzi Fulvio Massaro Sebastian Wittnebel Chloé Spilleboudt Philippe Lewalle Adriano Salaroli |
| author_sort | Fabio Andreozzi |
| collection | DOAJ |
| description | For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2-inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML. |
| first_indexed | 2024-03-09T11:45:53Z |
| format | Article |
| id | doaj.art-cb5eb05e363c4e54b9a4a642c22b5c3e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T11:45:53Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-cb5eb05e363c4e54b9a4a642c22b5c3e2023-11-30T23:23:35ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-03-01237388710.3390/ijms23073887New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored StrategyFabio Andreozzi0Fulvio Massaro1Sebastian Wittnebel2Chloé Spilleboudt3Philippe Lewalle4Adriano Salaroli5Hematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumHematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumHematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumHematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumHematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumHematology Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, BelgiumFor decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2-inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML.https://www.mdpi.com/1422-0067/23/7/3887acute myeloid leukemiaimmunotherapytarget therapyvenetoclax |
| spellingShingle | Fabio Andreozzi Fulvio Massaro Sebastian Wittnebel Chloé Spilleboudt Philippe Lewalle Adriano Salaroli New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy International Journal of Molecular Sciences acute myeloid leukemia immunotherapy target therapy venetoclax |
| title | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy |
| title_full | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy |
| title_fullStr | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy |
| title_full_unstemmed | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy |
| title_short | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy |
| title_sort | new perspectives in treating acute myeloid leukemia driving towards a patient tailored strategy |
| topic | acute myeloid leukemia immunotherapy target therapy venetoclax |
| url | https://www.mdpi.com/1422-0067/23/7/3887 |
| work_keys_str_mv | AT fabioandreozzi newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy AT fulviomassaro newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy AT sebastianwittnebel newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy AT chloespilleboudt newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy AT philippelewalle newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy AT adrianosalaroli newperspectivesintreatingacutemyeloidleukemiadrivingtowardsapatienttailoredstrategy |